Peptide guide
Retatrutide in the UAE: What Researchers Should Know
Retatrutide has become the most searched next-generation metabolic peptide in the UAE. Here is what researchers should know about its mechanism, current trials, and compliant sourcing.
What Retatrutide is
Retatrutide is a triple agonist of the GLP-1, GIP, and glucagon receptors, developed by Eli Lilly. In Phase 2 trials it produced substantially larger weight reductions than dual GLP-1 or GLP-1/GIP agonists over comparable timelines.
How it compares
- Semaglutide, GLP-1 only.
- Tirzepatide, GLP-1 plus GIP.
- Retatrutide, GLP-1 plus GIP plus glucagon, the third receptor is thought to add lipolytic and energy-expenditure effects.
Why UAE demand is rising
The UAE has one of the highest obesity prevalence rates in the region, and approved GLP-1 medicines are frequently in short supply at local pharmacies. That combination has pushed researchers, weight-management clinicians, and biohacking communities to investigate next-generation compounds like Retatrutide well before regulatory approval.
Regulatory status
Retatrutide is not yet an approved medicine anywhere in the world, including the UAE. Orion supplies it as a research-only reagent under the framework described in our legal-status guide. It is not intended for human therapeutic use.
Format and handling
Orion stocks Retatrutide as a pre-filled pen (solution, ready to use) to eliminate reconstitution variability across study sessions. Refrigerate at 2 to 8 degrees C and do not freeze.
Related products in stock in the UAE
Educational content for researchers and clinicians. Orion products are supplied strictly for Research Use Only (RUO). This article is not medical advice.